DRTS

Alpha Tau Medical Ltd.

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, and breast cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd. (DRTS) is rated C+ (2.7/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Growth (B); its weakest is Profitability (D+). The rating has held at C+ for 5 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.7 / 5.0
C+
Value
C+
Factor Score 2.5 / 5.0
Growth
B
Factor Score 3.4 / 5.0
Profitability
D+
Factor Score 1.7 / 5.0
Momentum
B
Factor Score 3.2 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -25.6
EV / EBITDA -24.2
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -1.2%
Price Return 12M 254.9%
Catalyst Signal 0.00
Market Cap $1.3B
TTM Revenue N/A
Price / Sales N/A
ROE -141.7%

Historical Factor Score Progression

Held C+ for 5 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-11 C+ (2.5) B (3.4) D+ (1.7) B (3.2) C+ (2.6) C+ (2.7)
2026-11-04 C+ (2.5) B (3.4) D+ (1.8) B (3.4) C+ (2.7) C+ (2.8)
2026-10-28 C+ (2.5) B (3.3) D+ (1.8) B+ (3.7) C+ (2.7) C+ (2.8)
2026-10-21 C+ (2.5) B (3.3) D+ (1.7) B (3.3) C+ (2.6) C+ (2.7)
2026-10-14 C+ (2.5) B (3.3) D+ (1.7) B (3.4) C+ (2.6) C+ (2.7)
Page 1 of 4